| content | ||||||||||||||||||||||
 |
|
| Type | Public (NYSE: AGN) |
|---|---|
| Founded | 1948 |
| Headquarters | Irvine, California |
| Key people | David E.I. Pyott, Chairman of the Board, CEO, F. Michael Ball, President |
| Industry | Pharmaceuticals |
| Products | Botox, Acular, Alocril, Prevage, Avage, Tazorac, Juvederm, Lap-band, Easyband,Restasis, Alphagan, Ganfort, Hydrafill, Optive |
| Revenue | $3.9 billion USD FY 2007 |
| Employees | 8,500 |
| Website | www.allergan.com |
Allergan, Inc., is a global specialty pharmaceutical company. Their product ranges include ophthalmic pharmaceuticals, dermatology products, and neurological products.
Contents |
Profile
The company's most notable neurologic product is Botox , used around the world to treat a variety of debilitating disorders associated with muscle overactivity and also well-known -- under the tradenames Botox Cosmetic and Vistabel -- for the treatment of facial lines.
Its most important manufacturing plants are in Waco, Texas, Westport, Ireland and San Jose, Costa Rica.
History
1950 Allergan launched its first product, NASAL DROPS
1962 Allergan achieves $1 Million in eye care sales
1966 Worldwide Corporate Headquarters was established in Irvine by acquiring a 28 ACRE parcel of land
1970 Allergan becomes Publicly traded and achievees $10 Million in sales
1978 Started Mfg in Ireland
1980 Subsidiaries are in 30 countries and products are marketed in more than 100 countries sales reach $100 Million
1980, the Company was acquired by SmithKline Beecham plc (then known as "SmithKline Corporation" and herein "SmithKline"). The Company operated as a wholly-owned subsidiary of SmithKline from 1980 until
1989 when Allergan again became a stand-alone public company through a spin-off distribution by SmithKline.
1992, the Company sold its contact lens business in North and South America.
1993, the Company sold its contact lens business outside of the Americas.
1994, the Company acquired the Ioptex Research worldwide intraocular lens product line.
1987 Allergan achieves $500 Million in sales
1995 Allergan achieves $1 Billion in sales
1995, the Company completed four acquisitions. In January 1995, the Company acquired Optical Micro Systems, Inc., a U.S.-based developer and manufacturer of phacoemulsification surgical equipment. In June 1995, the Company acquired Laboratorios Frumtost, S.A., a manufacturer of ophthalmic and other pharmaceutical products in Brazil. In August 1995, the Company purchased the assets of Herald Pharmacal, Inc., a U.S.-based developer and manufacturer of glycolic acid-based, aesthetic skin care products. In November 1995, the Company purchased the worldwide contact lens care product business of Pilkington Barnes Hind. Also in 1995, Allergan acquired 100% ownership interest in Santen-Allergan, its Japanese contact lens care joint venture.
1999 Allergan implemented a two-for-one stock split effected as a dividend to stockholders of record on November 18, 1999.
2002 Botox is born
2004 Allergan achieves $2 Billion in sales
2006 Allergan Achieves $3 Billion in sales
2006 Lap Band is born
2007 Breast implants developed(see "Inamed acquisition" below)
In March 2006, Allergan acquired aesthetic company, Inamed, to create a world leading aesthetic brand focused on facial aesthetics, breast aesthetics, and devices designed to treat obesity(lapband).
In February 2007, Allergan acquired the Swiss company Endoart SA based on the EPFL campus. It has special expertise in the field of telemetrically-controlled implants.
Allergan is reported to be investigating the cosmetic properties of Lumigan in clinical trials as of November 2007. 1
Products
- NATRELLE - Breast Implants (Silicone and Saline)
- LUMIGAN - anti-glaucoma medication containing the active ingredient bimatoprost.
- Alphagan P - anti-(glaucoma) medication containing the active ingredient (brimonidine)
- ACULAR
- ZYMAR
- Combigan - anti-(glaucoma) medication containing a combination of active ingredients (brimonidine) and (timolol)
- BOTOX - anti-spasm medication containing the active ingredient botulinum toxin.
- REFRESH - artificial tears containing carboxymethylcellulose
- CELLUVISC
- DRY EYE THERAPY
- Sensitive
- LACRI-LUBE
- LIQUIGEL
- PLUS
- P.M.
- REDNESS RELIEF
- TEARS
- OPTIVE - most advanced retail dry-eye treatment
- RESTASIS - dry eye treatment containing cyclosporine.
- JUVEDERM- used cosmetically for wrinkles and fine lines, also for lip augmentation
- TAZORAC- for severe acne and psoriasis
External links
- Natrelle homepage- Breast Implant Website
- Allergan homepage
- Endoart homepage
- Official Botox web site by Allergan
References
Citations
- ^ Wall Street Journal: Drug That Lengthens Eyelashes Sets Off Flutter RHONDA L. RUNDLE November 19, 2007; Page B1
